Crescent Biopharma, Inc. (CBIO) vs Monopar Therapeutics Inc. (MNPR)
A side-by-side comparison of Crescent Biopharma, Inc. and Monopar Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CBIO
Crescent Biopharma, Inc.
$14.30HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
MNPR
Monopar Therapeutics Inc.
$76.50HealthcareDelayed quote: Oct 6, 2026, 10:55 AM EDT
Total return — CBIO vs MNPR
growth of $100 · dividends reinvested · last 7yCBIO -91.5% (-29.6%/yr)MNPR -40.9% (-7.2%/yr)MNPR compounded faster over this window
Log scale — wide-divergence pair
CBIO MNPR
CBIO vs MNPR: by the numbers
- •CBIO is the larger company ($531M vs $512M market cap).
- •Both run net losses; MNPR's is the smaller (0.00% vs -1371.51% net margin).
Metrics side by side
Valuation
| Metric | CBIO | MNPR |
|---|---|---|
| P/S ratio | 44.70 | N/A |
| P/B ratio | 3.34 | 3.92 |
Profitability
| Metric | CBIO | MNPR |
|---|---|---|
| Gross margin | 100.00% | 0.00% |
| Operating margin | -1407.52% | 0.00% |
| Net margin | -1371.51% | 0.00% |
| ROE | -99.83% | -13.64% |
| ROIC | -102.59% | -16.89% |
Growth (annualized)
| Metric | CBIO | MNPR |
|---|---|---|
| Revenue CAGR (5Y) | 39.89% | N/A |
| Total return CAGR (5Y) | -24.40% | 27.38% |
Frequently asked
- How have CBIO and MNPR total returns compared?
- Over the past 5 years, CBIO delivered -24.40% and MNPR delivered 27.38% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Crescent Biopharma ROEMonopar Therapeutics ROECrescent Biopharma operating marginMonopar Therapeutics operating marginCrescent Biopharma revenue growthMonopar Therapeutics revenue growthCrescent Biopharma free cash flowMonopar Therapeutics free cash flow
Crescent Biopharma & Monopar Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.